Drug Development

A pivotal trial for a rare muscle disease failed its main goal, but promising data in a specific patient group offers a new, complex path forward.

Caidya appoints veteran Michael Clay as COO, leveraging his deep Asia-Pacific expertise to scale operations and solidify its position in the CRO market.

With promising data in cancer and eczema, all eyes are on Corvus Pharmaceuticals as it presents its lead drug at a major healthcare conference this week.

A $10,000 gift born from tragedy funds cutting-edge science, showing how community action is vital in the quest to end life-threatening food allergies.

With a novel skin drug launched, Pelthos Therapeutics heads to a key conference. Can its focused strategy convince Wall Street of its blockbuster potential?

New research reveals how clinical trial design inflates the placebo effect, offering a key to solving the 90% failure rate for anxiety and depression drugs.

With two blockbuster cancer drugs driving record revenue, all eyes are on Syndax's upcoming earnings call for its 2026 outlook and growth strategy.

Serina Therapeutics enrolls the first patient in a trial for SER-252, a novel Parkinson's therapy designed to improve symptoms without current side effects.

A landmark study finds nearly half of Americans use OTC drugs weekly, revealing a quiet revolution in self-care that challenges current healthcare policy.

A novel drug candidate targeting treatment-resistant kidney disease has begun its long journey through clinical trials, signaling a major strategic push.

New data on Spyre Therapeutics' SPY003 suggests a twice-yearly shot for IBD is possible, part of a broader strategy to challenge market giants.

NRx Pharmaceuticals gets a green light from the FDA to seek broader approval for its ketamine drug, NRX-100, using a novel real-world evidence approach.

Acurx Pharmaceuticals preps for pivotal Phase 3 trials for its novel C. diff antibiotic, Ibezapolstat, with global regulatory alignment in place.

A landmark trial for Roche’s Gazyva shows unprecedented success in treating primary membranous nephropathy, offering hope of preventing kidney failure.

Celcuity adds Seagen commercial veteran Charles Romp to its board, a strategic move signaling its pivot from R&D to market readiness for gedatolisib.

With strong Phase 1 data and key FDA backing, Trethera's TRE-515 is advancing as a 'pipeline-in-a-product' for a wide range of diseases.

The French biopharma giant posts strong 2025 results and forecasts over 13% growth, fueled by a booming pipeline and unexpected market advantages.

A massive $313M federal funding win brings hope to the ALS community, pushing total investment past $1.6B. But how close are we to a real breakthrough?

Following key FDA progress for its oral osteoporosis drug, Entera Bio's CEO and board members are buying up company stock, signaling deep confidence.

New 3D human tissue models show groundbreaking promise in predicting toxicity for advanced cancer therapies, heralding a major shift away from animal testing.